Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, et al. Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: Results from cancer and leukemia group B 100103 (alliance for clinical trials in oncology)/blood and marrow transplant clinical trial network 0502. J Clin Oncol. 2015;33:4167–75.
Google Scholar
Belete H, Burns LJ, Shanley R, Nayar M, McClune B, Lazaryan A, et al. Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients. Am J Hematol. 2017;92:E529–e33.
Google Scholar
Spellman SR, Xu K, Oloyede T, Ahn KW, Akhtar O, Bolon YT, et al. Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy – a report from the CIBMTR. Transpl Cell Ther. 2025;31:505–32.
Scott BL, Pasquini MC, Logan BRWJ, Devine SM, Porter DL, Maziarz RT, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154–61.
Google Scholar
Mushtaq MU, Kasaeian A, Amin MK, Alemi H, Khavandgar N, Ur Rehman A, et al. Factors associated with graft-versus-host disease after related donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based GvHD prophylaxis. Blood. 2024;144:3517.
Google Scholar
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42:377–81.
Google Scholar
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inf. 2019;95:103208.
Google Scholar
Brunner AM, Kim HT, Coughlin E, Alyea EP 3rd, Armand P, et al. Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transpl. 2013;19:1374–80.
Google Scholar
Artz A, Logan BR, Saber W, Geller N, Bellach A, Kou J, et al. The composite health risk assessment model (CHARM) to predict 1-year non-relapse mortality (NRM) among older recipients of allogeneic transplantation: a prospective BMT-CTN study 1704. Blood. 2023;142:109.
Google Scholar
Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, et al. Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer. 2020;126:5077–87.
Google Scholar
Backhaus D, Brauer D, Pointner R, Bischof L, Vucinic V, Franke GN, et al. A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older. Bone Marrow Transpl. 2023;58:30–8.
Google Scholar
